Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (191-200 of 297) with videos related to

Pageof 30
Sort By:
American Journal of Respiratory and Critical Care Medicine|January 18, 2024
Hospitalization Rates in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation RegistryChristopher S King, Rosalinda V Ignacio, Vikramjit Khangoora, et al.
Respiratory Medicine|May 10, 2015
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisSteven D Nathan, Roland M du Bois, Carlo Albera, et al.
Chest|February 25, 2020
A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary FibrosisSteven D Nathan, Kevin R Flaherty, Marilyn K Glassberg, et al.
Respiratory Medicine|September 17, 2014
Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary diseaseStephanie Shin, Christopher S King, A Whitney Brown, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
Annals of the American Thoracic Society|August 14, 2024
Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled TrialSteven D Nathan, Natasa Rajicic, Rosemarie Dudenhofer, et al.
Heliyon|August 21, 2023
Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registryChristopher S King, Emily White, Shambhu Aryal, et al.
Pulmonary Circulation|April 19, 2021
Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of lifeHilary M DuBrock, Steven D Nathan, Bryce B Reeve, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
Chest|July 30, 2011
Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndromeMichael Eberlein, Solbert Permutt, Mayy F Chahla, et al.
Pageof 30

Showing results (191-200 of 297) with videos related to

Sort By:
Pageof 30
American Journal of Respiratory and Critical Care Medicine|January 18, 2024
Hospitalization Rates in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation RegistryChristopher S King, Rosalinda V Ignacio, Vikramjit Khangoora, et al.
Respiratory Medicine|May 10, 2015
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisSteven D Nathan, Roland M du Bois, Carlo Albera, et al.
Chest|February 25, 2020
A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary FibrosisSteven D Nathan, Kevin R Flaherty, Marilyn K Glassberg, et al.
Respiratory Medicine|September 17, 2014
Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary diseaseStephanie Shin, Christopher S King, A Whitney Brown, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
Annals of the American Thoracic Society|August 14, 2024
Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled TrialSteven D Nathan, Natasa Rajicic, Rosemarie Dudenhofer, et al.
Heliyon|August 21, 2023
Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registryChristopher S King, Emily White, Shambhu Aryal, et al.
Pulmonary Circulation|April 19, 2021
Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of lifeHilary M DuBrock, Steven D Nathan, Bryce B Reeve, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
Chest|July 30, 2011
Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndromeMichael Eberlein, Solbert Permutt, Mayy F Chahla, et al.
Pageof 30